Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen (levonorgestrel‑releasing intrauterine system) presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term contraception and reduces heavy menstrual bleeding in women of reproductive age. The device releases levonorgestrel locally, delivering approximately 20 µg per day initially and remaining effective for up to five years.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides regulatory documentation for global distribution.

Mirena, a levonorgestrel‑releasing intrauterine system, is used in the reproductive health field for contraception and menstrual management.

- Contraception: provides highly effective, reversible birth control for up to five years. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with menorrhagia. - Endometrial hyperplasia (benign): may be used as part of management to suppress endometrial proliferation. - Hormone‑dependent uterine bleeding: helps regulate irregular bleeding patterns caused by hormonal fluctuations.

Adverse reactions reported with Mirena are categorized by frequency.

Common Side Effects: - Irregular bleeding or spotting: changes in bleeding pattern during the first months. - Amenorrhea: absence of menstrual periods after continued use. - Pelvic pain or cramping: discomfort related to device insertion or presence. - Headache: mild to moderate headache episodes.

Serious or Rare Side Effects: - Uterine perforation: rare injury to the uterine wall during insertion. - Expulsion of the device: device may be partially or completely expelled. - Pelvic inflammatory disease: infection that can develop after insertion.

Mirena requires careful patient selection and follow‑up to minimize risks.

- Contraindication: Do not use in women who are pregnant or have known or suspected pregnancy. - Screening: Verify absence of active pelvic infection before insertion. - Follow‑up: Schedule pelvic examination 4–6 weeks after insertion to confirm placement. - Removal: Ensure device is removed promptly if pregnancy occurs or if serious complications arise. - Patient counseling: Inform about possible changes in bleeding pattern and signs of infection. - Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Mirena may interact with drugs that affect levonorgestrel metabolism.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce levonorgestrel effectiveness. - Rifampin: can decrease levonorgestrel concentrations, risking contraceptive failure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel levels, potentially heightening side effects. - Antiretroviral protease inhibitors: may alter hormone metabolism, requiring clinical monitoring. - Hormonal therapies (e.g., estrogen‑containing contraceptives): concurrent use may increase risk of thromboembolic events.